The aim of this study was to assess associations between patient characteristics, intensification of blood glucose-lowering treatment through oral glucose-lowering therapy and/or insulin and effective glycaemic control in type 2 diabetes.11 140 patients from the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) trial who were randomized to intensive glucose control or standard glucose control and followed up for a median of 5 years were categorized into two groups: effective glycaemic control [haemoglobin A1c (HbA1c) ≤ 7.0

作者：S, van Dieren；A P, Kengne；J, Chalmers；J W J, Beulens；T M E, Davis；G, Fulcher；S R, Heller；A, Patel；S, Colagiuri；P, Hamet；G, Mancia；M, Marre；B, Neal；B, Williams；L M, Peelen；Y T, van der Schouw；M, Woodward；S, Zoungas

来源：Diabetes, obesity & metabolism 2014 年 16卷 5期